People
Prometheus Biosciences names new chief development officer, diagnostics, and medical laboratory director
11 December 2019 -

Prometheus Biosciences Inc, a biopharmaceutical company involved in the discovery, development, and commercialisation of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases, announced yesterday that it has named Thierry Dervieux, PharmD, PhD, DABCC as its new chief development officer, diagnostics, and medical laboratory director.

Dr Dervieux joins Prometheus Biosciences from Exagen Diagnostics where he served as chief scientific officer and medical director. Prior to joining Exagen, Dr Dervieux was vice president of research and development at Cypress Bioscience Inc and senior director of research and development with Proprius Pharmaceuticals Inc. Prior to that, he served as principal scientist and director of research and development at Prometheus Laboratories.

Mark McKenna, chief executive officer of Prometheus Biosciences, said, 'Thierry's deep expertise in the development of innovative diagnostic assays and drug monitoring tools will benefit us greatly as we continue to advance our novel precision medicine platform for GI and autoimmune conditions. We are thrilled to welcome Thierry and we look forward to his contributions as we take Prometheus to the next level.'

Login
Username:

Password: